Evogene (NASDAQ:EVGN – Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($1.06) EPS for the quarter, Zacks reports. Evogene had a negative net margin of 233.66% and a negative return on equity of 70.96%. The firm had revenue of $0.91 million for the quarter.
Evogene Price Performance
Shares of NASDAQ:EVGN opened at $3.50 on Friday. The business’s 50-day moving average is $5.40 and its 200 day moving average is $6.82. Evogene has a 1 year low of $3.45 and a 1 year high of $10.40. The firm has a market capitalization of $144.26 million, a P/E ratio of -7.72 and a beta of 1.40.
Analysts Set New Price Targets
Separately, StockNews.com assumed coverage on shares of Evogene in a research report on Thursday. They set a “sell” rating for the company.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Read More
- Five stocks we like better than Evogene
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- Election Stocks: How Elections Affect the Stock Market
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
- Consumer Staples Stocks, Explained
- Ross Stores Investors Win Big as Off-Price Retailers Outperform
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
